The assessment of neoadjuvant treatment's response is critical for selecting the most suitable therapeutic options for patients with breast cancer to reduce the need for invasive local therapies. Breast magnetic resonance imaging (MRI) is so far one of the most accurate approaches for assessing pathological complete response, although this is limited by the qualitative and subjective nature of radiologists' assessment, often making it insufficient for deciding whether to forgo additional locoregional therapy measures. To increase the accuracy and prediction of radiomic MRI with the aid of machine learning models and deep learning methods, as part of artificial intelligence, have been used to analyse the different subtypes of breast cancer and the specific changes observed before and after therapy. This review discusses recent advancements in radiomic MRI models for presurgical response assessment for patients with early breast cancer receiving preoperative treatments, with a focus on their implications for clinical practice.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2025.104681DOI Listing

Publication Analysis

Top Keywords

breast cancer
16
radiomic mri
12
mri models
8
models presurgical
8
presurgical response
8
response assessment
8
assessment patients
8
patients early
8
early breast
8
breast
6

Similar Publications

Background: Tumor metastasis is one of the main causes of death in cancer patients; however, the mechanism controlling metastasis is unclear. The posttranscriptional regulation of metastasis-related genes mediated by AT-rich interactive domain-containing protein 4A (Arid4a), an RNA-binding protein (RBP), has not been elucidated.

Methods: Bioinformatic analysis, qRT-PCR, immunohistochemistry, and immunoblotting were employed to determine the expression of Arid4a in breast tumor tissues and its association with the survival of cancer patients.

View Article and Find Full Text PDF

In recent years, tumor immunotherapy has made significant breakthroughs in the treatment of malignant tumors. However, individual differences in efficacy have been observed in clinical practice. There is increasing evidence that gut microbial metabolites influence the efficacy of distal tumor immunotherapy via the gut-liver axis, the gut-brain axis and the gut-breast axis, a process that may involve modulating the expression of immune cells and cytokines in the tumor microenvironment (TME).

View Article and Find Full Text PDF

High tumour mutational burden (TMB-high), identified through comprehensive genomic profiling (CGP), is a biomarker that predicts the efficacy of immune checkpoint inhibitors. CGP testing is recommended for rare cancers with limited effective treatment options. Here, we provide the first report of a malignant phyllodes tumour of the breast demonstrating TMB-high status and effective treatment with pembrolizumab.

View Article and Find Full Text PDF
Article Synopsis
  • Advances in breast cancer treatment have not significantly improved outcomes for metastatic cases, which still lead to high mortality rates.
  • Physical activity has been linked to reduced breast cancer risk and improved treatment outcomes, prompting a study on its effects on metastatic triple negative breast cancer (TNBC).
  • Results show that increasing physical activity after surgical interventions can significantly enhance metastasis-free survival in mice, suggesting exercise may play a crucial role in delaying cancer progression.
View Article and Find Full Text PDF

Unlabelled: Nasal polyp (NP) is a pathological benign mass that affects the nasal cavity and paranasal sinuses. This lesion is occasionally associated with chronic rhinosinusitis (CRS), which is named chronic rhinosinusitis with nasal polyps (CRSwNP). Proliferating cell nuclear antigen (PCNA) indicates abnormal cell proliferation which may help assess the nasopharyngeal lesions and upper airway cancers.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!